PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 12, 2025Journal of Nanobiotechnology8 citationsOpen Access

AND logic-gated CRISPR/Cas9 and hybridization chain reaction system for precise ctDNA detection

View Full Paper
TJTianliang JiYZYujia ZhangYWYixiu Wang

Key Points

  • This research aims to enhance the detection of circulating tumor DNA (ctDNA) for cancer diagnostics.
  • Novel detection method integrating CRISPR/Cas9 with hybridization chain reaction (HCR) isothermal amplification.
  • Employs AND logic-gated system to minimize off-target effects of Cas9.
  • Tests included specificity validation through simulated clinical samples.
  • Achieves high sensitivity and specificity for detecting ctDNA.
  • Successfully identifies mutations including KRAS G12D and EGFR T790M among wild-type sequences.
  • Delivers reliable detection with low limits of detection, as low as 1 fM.

Abstract

Circulating tumor DNA (ctDNA) is a critical biomarker for liquid biopsies, enabling the non-invasive acquisition of cancer-related information from blood samples. Precise detection of ctDNA, particularly the identification of single-nucleotide variations (SNVs), is crucial for early cancer diagnosis, therapeutic monitoring, and prognostic evaluation. However, current ctDNA detection methods often encounter challenges such as complex procedures, difficult data analysis, and false-positive signals during pre-amplification. In this study, we introduce a novel detection method based on AND logic-gated integration of interspaced short palindromic repeats and associated proteins (CRISPR/Cas9) system with hybridization chain reaction (HCR) isothermal amplification. This strategy enhances the specific and sensitive detection of ctDNA. The incorporation of the AND logic gate effectively minimizes the off-target effects of Cas9 and enables the differentiation of single-nucleotide mutations, such as KRAS G12D, even in complex serum environments. Our system exhibits high sensitivity and specificity, achieving a limit of detection as low as 1 fM and capable of identifying SNVs mutations with allele fractions as low as 0.1% among wild-type sequences. Furthermore, we validated the specificity of our approach by successfully detecting various mutations, including KRAS G12C, KRAS G12D, EGFR T790M and TP53 R273H, in simulated clinical samples. These findings highlight a reliable method for precise ctDNA detection, offering high specificity, selectivity, and accuracy, thus paving the way for potential cancer diagnostic application.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ji et al. (2025) studied this question.

synapsesocial.com/papers/6940190c2d562116f28f62c9https://doi.org/10.1186/s12951-025-03912-y
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An “AND” logic gate–based supramolecular therapeutic nanoplatform for combatting drug-resistant non–small cell lung cancer2024 · 31 citations
  2. 2A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer2023 · 78 citations
  3. 3NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing2023 · 236 citations
  4. 4Tumor Suppressive Functions of p532009 · 580 citations
  5. 5Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants2020 · 1,308 citations